Physician profile
Dina Epstein
NPI 1497141188
$2,654.17
in general payments reported to CMS, 2019-2025
27 companies · $666 in 2025
The $666 reported for 2025 was more than what 86% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $152 · 2020: $97.38 · 2021: $367 · 2022: $445 · 2023: $444 · 2024: $482 · 2025: $666.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,592.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,592.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sumitomo Pharma America, INC. | $328.83 | 2023-2025 | Myfembree |
| Biogen, INC. | $232.72 | 2024-2025 | Zurzuvae |
| Bayer Healthcare Pharmaceuticals INC. | $224.09 | 2021-2025 | |
| Organon LLC | $218.28 | 2021-2025 | Nexplanon, Jada System |
| Pfizer INC. | $209.49 | 2021-2025 | |
| Abbvie INC. | $204.88 | 2019-2023 | |
| Mayne Pharma Commercial LLC | $177.14 | 2022-2025 | |
| Hologic Sales and Service, LLC | $160.16 | 2019-2025 | Aptima, Thinprep 2000 Processor |
| Exeltis, USA INC. | $146.26 | 2022-2025 | Slynd |
| Aspira Women'S Health INC | $90.52 | 2021 | |
| Evofem Biosciences, INC. | $86.32 | 2020-2022 | |
| Scynexis, INC. | $76.50 | 2022 | |
| Merck Sharp & Dohme LLC | $74.30 | 2019-2022 | |
| Astellas Pharma US INC | $71.29 | 2024-2025 | Veozah |
| Shield Therapeutics INC | $61.85 | 2024 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Avion Pharmaceuticals | $56.85 | 2021-2022 | |
| Intuitive Surgical, INC. | $34.77 | 2023 | Da Vinci Surgical System |
| Minerva Surgical, INC | $32.84 | 2021-2023 | |
| Mylan Pharmaceuticals INC. | $32.80 | 2022 | |
| Innovation Technologies INC | $21.64 | 2025 | Irrisept |
| Urovant Sciences INC | $19.39 | 2021 | |
| Pacira Pharmaceuticals Incorporated | $18.34 | 2019 | |
| Solventum Corporation | $18.26 | 2024 | Prevena |
| Dexcom, INC. | $16.27 | 2024 | Dexcom G6 Transmitter |
| Allergan, INC. | $13.69 | 2019 | |
| Kci USA, INC. | $13.50 | 2020 | |
| Therapeuticsmd, INC. | $13.19 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dina Epstein listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.